Your browser doesn't support javascript.
loading
Effect of minocycline on changes in affective behaviors, cognitive function, and inflammation in breast cancer survivors undergoing chemotherapy: a pilot randomized controlled trial.
Melink, Zihan; Lustberg, Maryam B; Schnell, Patrick M; Mezzanotte-Sharpe, Jessica; Orchard, Tonya S.
Afiliación
  • Melink Z; Department of Human Sciences, The Ohio State University, Columbus, OH, 43210, USA.
  • Lustberg MB; Yale School of Medicine, Center for Breast Cancer, New Haven, CT, 06511, USA.
  • Schnell PM; Division of Biostatistics, College of Public Health, The Ohio State University, Columbus, OH, 43210, USA.
  • Mezzanotte-Sharpe J; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
  • Orchard TS; Department of Human Sciences, The Ohio State University, Columbus, OH, 43210, USA. orchard.6@osu.edu.
Breast Cancer Res Treat ; 208(3): 605-617, 2024 Dec.
Article en En | MEDLINE | ID: mdl-39143391
ABSTRACT

PURPOSE:

Minocycline suppresses chemotherapy-induced neuroinflammation in preclinical models, but its effects in cancer survivors are unknown. This study evaluated the longitudinal effects of minocycline on affective behaviors, cognitive functions, and inflammation in women with breast cancer (BC) undergoing chemotherapy.

METHODS:

This is a pilot, double-blind, randomized controlled trial of oral minocycline (100 mg BID) versus placebo for chemotherapy-induced affective disorders in women initiating chemotherapy for stage I-III BC. Participants received minocycline or placebo up to one week before chemotherapy, continuing through cycle 4 (C4). Epidemiologic Studies Depression Scale (CES-D) and State-Trait Anxiety Inventory (STAI) were assessed at baseline, each cycle of chemotherapy (C1-C4), 2-3-week post-chemotherapy (end of chemotherapy), and 6-month post-chemotherapy (6 M) as the primary outcomes. Sub-group analysis of CES-D and STAI based on the severity of symptoms was also performed. Changes in self-reported cognition and serum inflammatory markers were also evaluated.

RESULTS:

Fifty-seven women enrolled and 55 completed the study. Except for Interleukin-8 (p ≤ 0.03), changes in inflammatory markers, cognitive function, CES-D, and STAI were not significantly different between groups from baseline to any cycle or post-chemotherapy time point (all p > 0.05), adjusting for baseline scores. Increases in serum Interleukin-8 from baseline to C4 and 6 M were ameliorated by minocycline (p < 0.05). The sub-group symptomatic for depression (CES-D > = 16 at baseline) treated with minocycline had a greater reduction in CES-D score compared to placebo from baseline to 6 M (p = 0.01).

CONCLUSION:

Despite attenuation of IL-8, minocycline did not alter self-reported affective symptoms or cognition in this cohort of BC survivors undergoing chemotherapy. The effect of minocycline on BC survivors symptomatic for depression before chemotherapy warrants further investigation.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Cognición / Supervivientes de Cáncer / Inflamación / Minociclina Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Treat Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Cognición / Supervivientes de Cáncer / Inflamación / Minociclina Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Treat Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Países Bajos